Joseph C.  Schick net worth and biography

Joseph Schick Biography and Net Worth

Director of BioLife Solutions
Mr. Schick joined the Board in November 2013. He has 13 years of experience as a Chief Financial Officer spanning four different mid-sized companies in various industries. Prior to his CFO experience, Mr. Schick was in various roles for seven years at Expedia (NASDAQ: EXPE), including Senior Vice President of Finance. From this background, Mr. Schick has significant experience with SEC reporting, strategic planning, and mergers and acquisitions. Mr. Schick started his career with Arthur Andersen and is a CPA who received his B.S. in Accounting from the University of Illinois. He is also on various non-profit boards and completed the Director Certification program at UCLA. The Board has determined that Mr. Schick should serve as a director because of his financial experience with public companies.

What is Joseph C. Schick's net worth?

The estimated net worth of Joseph C. Schick is at least $325,256.25 as of August 25th, 2021. Mr. Schick owns 11,875 shares of BioLife Solutions stock worth more than $325,256 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Schick may own. Learn More about Joseph C. Schick's net worth.

How do I contact Joseph C. Schick?

The corporate mailing address for Mr. Schick and other BioLife Solutions executives is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. BioLife Solutions can also be reached via phone at (425) 402-1400 and via email at [email protected]. Learn More on Joseph C. Schick's contact information.

Has Joseph C. Schick been buying or selling shares of BioLife Solutions?

Joseph C. Schick has not been actively trading shares of BioLife Solutions during the last quarter. Most recently, Joseph C. Schick sold 3,250 shares of the business's stock in a transaction on Thursday, October 7th. The shares were sold at an average price of $40.04, for a transaction totalling $130,130.00. Learn More on Joseph C. Schick's trading history.

Who are BioLife Solutions' active insiders?

BioLife Solutions' insider roster includes Sarah Aebersold (VP), Todd Berard (CMO), Roderick de Greef (CFO), Karen Foster (Insider), Andrew Hinson (Director), Aby Mathew (VP), Michael Rice (CEO), Joseph Schick (Director), Marcus Schulz (CRO), and Troy Wichterman (CFO). Learn More on BioLife Solutions' active insiders.

Are insiders buying or selling shares of BioLife Solutions?

In the last twelve months, insiders at the medical equipment provider sold shares 75 times. They sold a total of 143,570 shares worth more than $2,926,356.42. The most recent insider tranaction occured on December, 16th when EVP Aby J Mathew sold 7,604 shares worth more than $207,817.32. Insiders at BioLife Solutions own 2.2% of the company. Learn More about insider trades at BioLife Solutions.

Information on this page was last updated on 12/16/2024.

Joseph C. Schick Insider Trading History at BioLife Solutions

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/7/2021Sell3,250$40.04$130,130.00View SEC Filing Icon  
8/25/2021Sell1,875$52.54$98,512.5011,875View SEC Filing Icon  
8/18/2021Sell625$44.11$27,568.7513,750View SEC Filing Icon  
5/24/2021Sell1,250$31.61$39,512.509,375View SEC Filing Icon  
9/18/2019Sell3,287$21.00$69,027.008,588View SEC Filing Icon  
5/16/2019Sell2,900$18.01$52,229.008,775View SEC Filing Icon  
5/7/2019Sell200$18.00$3,600.007,075View SEC Filing Icon  
4/16/2019Sell22,053$17.11$377,326.8318,928View SEC Filing Icon  
8/24/2018Sell4,765$25.96$123,699.4010,000View SEC Filing Icon  
6/1/2018Sell6,858$10.07$69,060.0614,765View SEC Filing Icon  
See Full Table

Joseph C. Schick Buying and Selling Activity at BioLife Solutions

This chart shows Joseph C Schick's buying and selling at BioLife Solutions by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioLife Solutions Company Overview

BioLife Solutions logo
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $27.39
Low: $25.13
High: $28.63

50 Day Range

MA: $24.96
Low: $20.47
High: $27.47

2 Week Range

Now: $27.39
Low: $14.50
High: $28.88

Volume

1,077,464 shs

Average Volume

386,862 shs

Market Capitalization

$1.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91